Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neurovascular Regulation During Exercise in Chronic Kidney Disease
NCT02947750Phase 2Recruiting
- Sponsor
- Emory University
- Start
- Oct 2016
- Primary completion
- Apr 2027
- Modality
- Allosteric Modulators, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sapropterin in chronic kidney disease (CKD) (6 arms), sponsored by Emory University. Primary endpoints: Change in functional sympatholysis at 12 weeks, Change in vascular alpha 1 adrenergic responsiveness at 12 weeks and 1 more. Started Oct 2016; status: recruiting.
02
Drugs
sapropterin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT02947750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02947750.